Molecular Biology Reports

, Volume 41, Issue 11, pp 7141–7151 | Cite as

Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population

  • Guo-Hua Zheng
  • Shang-Quan Xiong
  • Hai-Ying Chen
  • Li-Juan Mei
  • Ting Wang


The circulating level of platelet-activating factor acetylhydrolase (PAF-AH) is a novel biomarker to predict the presence of coronary heart disease. PAF-AH gene polymorphisms may be responsible for the variance of circulating PAF-AH levels in individuals. However, the association of PAF-AH gene polymorphisms with circulating PAF-AH levels and the susceptibility to coronary heart disease (CHD) remains unsolved. Blood stasis syndrome (BSS) of CHD is the most common type of TCM syndromes, and a previous study discovered its relationship with the elevated circulating PAF-AH levels. However, the association of gene polymorphisms and CHD with BSS is unclear at present. In this study, four polymorphisms (R92H, I198T, A379V, V279F) of the PAF-AH gene were genotyped in 570 CHD patients, of which 299 had BSS. In addition, 317 unaffected individuals from the same hospitals served as controls. Plasma PAF-AH levels were measured in 155 controls and 271 CHD patients selected randomly, including 139 CHD patients with BSS. In the Chinese Han population, plasma PAF-AH levels in CHD patients with BSS or without BSS were significantly higher (12.9 ± 6.5 and 11.1 ± 5.0 μM, respectively) than in controls (9.3 ± 5.2 μM); this difference still remained significant after adjustment for traditional risk factors or the inflammatory factors. The R92H polymorphism was highly related to the plasma PAF-AH levels and the risk of CHD, especially among patients with BSS, even with the adjustment for the effects of traditional factors. The I198T polymorphism was highly associated with risk of CHD with BSS, but was associated with neither the risk of CHD with no BSS nor with elevated plasma PAF-AH levels.


Platelet-activating factor acetylhydrolase Gene polymorphism Coronary heart disease Blood stasis syndrome Association 

Abbreviations and acronyms


Body mass index


Blood stasis syndrome


Coronary heart disease

95 % Cl

95 % Confidence interval


Deoxyribonucleotide triphosphates




Genome-wide association study


High density lipoprotein cholesterol


Hardy–weinberg equilibrium


High sensitivity C-reaction protein


Interleukin 6


Linkage disequilibrium


Low density lipoprotein cholesterol


Lipoprotein-associated phospholipase A2


The minor allele frequency


Odds ratio


Platelet activating factor acetylhydrolase


Polymerase chain reaction


Shrimp alkaline phosphatase


Standard deviation


Single nucleotide polymorphism


Total cholesterol


Traditional Chinese medicine





Sources of Funding: This study was supported by research funds from the National Natural Science Foundation of China (Grant No: 81072726, National Natural Science Foundation of China, Beijin, China) and the Natural Science Foundation of Fujian province (Grant No: 2009J01163, Fujian Provincial Department of Science & Technology, Fujian, China). But the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest


Supplementary material

11033_2014_3597_MOESM1_ESM.doc (72 kb)
Supplementary material 1 (DOC 72 kb)


  1. 1.
    Kones R (2011) Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Dev Ther 5:325–380CrossRefGoogle Scholar
  2. 2.
    Zhang XH, Lu ZL, Liu L (2008) Coronary heart disease in China. Heart 94:1126–1131PubMedCrossRefGoogle Scholar
  3. 3.
    Lloyd-Jones DM, Hong Y, Labarthe D et al (2010) American heart association strategic planning task force and statistics committee defining and setting national goals for cardiovascular health promotion and disease reduction: the American heart association’s strategic impact goal through 2020 and beyond. Circulation 121:586–613PubMedCrossRefGoogle Scholar
  4. 4.
    Marenberg ME, Risch N, Berkman LF et al (1994) Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330:1041–1046PubMedCrossRefGoogle Scholar
  5. 5.
    Schnabel R, Dupuis J, Larson MG et al (2009) Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham heart study. Atherosclerosis 204:601–607PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Schunkert H, Konig IR, Kathiresan S et al (2011) Large-scale association analyses identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43:333–338PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Schunkert H, Erdmann J, Samani NJ (2010) Genetics of myocardial infarction: a progress report. Eur Heart J 31:918–925PubMedCrossRefGoogle Scholar
  8. 8.
    Dandona S, Stewart AF, Roberts R (2010) Genomics in coronary artery disease: past, present and future. Can J Cardiol suppl A:56A–59ACrossRefGoogle Scholar
  9. 9.
    Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  10. 10.
    Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143PubMedCrossRefGoogle Scholar
  11. 11.
    Zalewski A, Macphee C (2005) Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25:923–931PubMedCrossRefGoogle Scholar
  12. 12.
    Dohi T, Miyauchi K, Ohkawa R et al (2012) Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography. Ann Clin Biochem 49:527–533PubMedCrossRefGoogle Scholar
  13. 13.
    Packard CJ, O’Reilly DS, Caslake MJ et al (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med 343:1148–1155PubMedCrossRefGoogle Scholar
  14. 14.
    Daniels LB, Laughlin GA, Sarno MJ et al (2008) Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population. J Am Coll Cardiol 51:913–919PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lavi S, McConnel JP, Rihal CS et al (2007) Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115:2715–2721PubMedCrossRefGoogle Scholar
  16. 16.
    The Lp-PLA2 studies Collaboration, Thompson A, Gao P, Orfei L et al (2010) Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375:1536–1544PubMedCrossRefGoogle Scholar
  17. 17.
    Ninio E, Tregouet D, Carrier JL et al (2004) Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 13:1341–1351PubMedCrossRefGoogle Scholar
  18. 18.
    Abuzeid AM, Hawe E, Humphries SE, Talmud PJ (2003) Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the North and South of Europe. Atherosclerosis 168:283–288PubMedCrossRefGoogle Scholar
  19. 19.
    Hoffimann MM, Winkler K, Renner W et al (2009) Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen risk and cardiovascular health study). J Thromb Haemost 7:41–48CrossRefGoogle Scholar
  20. 20.
    Li S, Stuart L, Zhang Y et al (2009) Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype. J Clin Pharm Ther 34:447–455PubMedCrossRefGoogle Scholar
  21. 21.
    Grallert H, Dupuis J, Bis JC et al (2012) Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J 33:238–251PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Suchindran S, Rivedal D, Guyton JR et al (2010) Genome-wide association study of Lp-PLA2 activity and mass in the Framingham heart study. PLoS Genet 6:e1000928PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Unno N, Nakamura T, Kaneko H et al (2000) Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japanese. J Vasc Surg 32:263–267PubMedCrossRefGoogle Scholar
  24. 24.
    Yamada Y, Yoshida H, Ichihara S et al (2000) Correlation between plasma platelet-activiting factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150:209–216PubMedCrossRefGoogle Scholar
  25. 25.
    Yamada Y, lzawa H, Ichihara S et al (2002) Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347:1916–1923PubMedCrossRefGoogle Scholar
  26. 26.
    Jang Y, Kim OY, Koh SJ et al (2006) The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 91:3521–3527PubMedCrossRefGoogle Scholar
  27. 27.
    Hou L, Chen S, Yu H et al (2009) Association of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 125:11–20PubMedCrossRefGoogle Scholar
  28. 28.
    Fu CG, Gao ZY, Wang PL et al (2012) Study on the diagnostic criteria for coronary heart disease of blood stasis syndrome. Chin J Integr Tradit West Med 32:1285–1286Google Scholar
  29. 29.
    Hu WJ, Zhang BT, Wu L (2012) The relationship between inflammation, platelet activation and blood stasis syndrome. J Nanchang Univ 52:81–84Google Scholar
  30. 30.
    Hong YD, Huang YS, Wu H et al (2005) Clinical studies on relationship between TCM syndromes of coronary heart disease and inflammatory factors. J Guangzhou Univ Tradit Chin Med 22:81–86Google Scholar
  31. 31.
    Xie H, Wang W, Zhao HH et al (2010) Relationship between plasma apoA-1, α1-antitrypsin and inflammation in blood stasis syndrome of coronary heart disease. J Beijing Univ Tradit Chin Med 33:253–256Google Scholar
  32. 32.
    Pen WJ, Xing ZH, Liao X, Liu WP (2011) Effect of Yiqi Huoxue therapy on serum IL-6, ICAM-1 and TNF-αin patients with stable angina pectoris in qi deficiency and blood stasis. J Tradit Chin Med Univ Hunan 31:49–51Google Scholar
  33. 33.
    Zhao HY, Wang WH, Chen WQ et al (2011) Effect of Shanzha Xiaozhi capsule on homocysteine and hypersensitivity-C reactive protein in patients of Non-acute coronary heart disease with phlegm and Blood Stasis Syndrome. J New Chin Med 43:9–11Google Scholar
  34. 34.
    Ma XJ, Yin HJ, Chen KJ (2007) Research progress of correlation between blood stasis syndrome and inflammation. Chin J Integr Tradit West Med 27:669–672Google Scholar
  35. 35.
    International Society of Cardiology (1981) Naming and diagnosic criteria of ischaemic heart disease. Chin J Cardiol 9:75–76Google Scholar
  36. 36.
    Disease Special Committee (1991) Chinese Association of the Integrative Medicine. Standard of syndrome differentiation on coronary heart disease of Chinese medicine. Chin J Integr Tradit West Med 11:257Google Scholar
  37. 37.
    Karasawa k (2006) Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biohphys Acta 1761:1359–1372CrossRefGoogle Scholar
  38. 38.
    Chris J, Packard DS, Denis SJ, Reily MD (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Eng J Med 343:1148–1155CrossRefGoogle Scholar
  39. 39.
    Magjid M, Ali M, Willerson JT (2010) Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease : a systematic review of the literature. Tex Heart Inst J 37:25–39Google Scholar
  40. 40.
    Caslake MJ, Packard CJ, Suckling KE et al (2000) Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150:413–419PubMedCrossRefGoogle Scholar
  41. 41.
    Brilakis ES, McConnell JP, Lennon RL et al (2005) Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26:137–144PubMedCrossRefGoogle Scholar
  42. 42.
    Tsimihodimos V, Karabina SA, Tambaki AP et al (2002) Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 43:256–263PubMedGoogle Scholar
  43. 43.
    Oei HH, Vander MM, Hofman A et al (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111:570–575PubMedCrossRefGoogle Scholar
  44. 44.
    Wang T, Karino K, Yamasaki M et al (2009) Effects of G994T in the LP-PLA2 gene on the plasma oxidized LDLL level and carotid intima-media thickness in Japanese: the Shimane study. Am J Hypertens 22:742–747PubMedCrossRefGoogle Scholar
  45. 45.
    Jang Y, Waterworth D, Lee JE et al (2011) Carriage of the V279F null allele within the gene encoding LP-PLA2 is protective from coronary artery disease in South Korean males. PLoS one 6(4):e18208PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Wootton PT, Stephens JW, Hurel SJ et al (2006) LP-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. Atherosclerosis 189:149–156PubMedCrossRefGoogle Scholar
  47. 47.
    Kruse S, Mao XQ, Heinzmann A et al (2006) The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66:1522–1530CrossRefGoogle Scholar
  48. 48.
    Campo S, Sardo MA, Trimarchi G et al (2008) Platelet activating factor–acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicllian octogenarians. Aging Clin Exp Res 20:171–177PubMedCrossRefGoogle Scholar
  49. 49.
    Lee KK, Fortmann SP, Varady A, Fair JM, Go AS et al (2011) Racial variation in lipoprotein–associated phospholipase A2 in older adults. BMC Cardiovasc Disord 11:38PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Sutton BS, Crosslin DR, Shah SH et al (2008) Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet 17:1318–1328PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Yamamoto I, Fujitsu J, Nohnen S, Igarashi T, Inaba M et al (2003) Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabet Res Clin Pract 59:219–224CrossRefGoogle Scholar
  52. 52.
    Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL et al (2010) PLA2G7 genotype, lipoprotein–associated phospholipase A2 activity, and coronary heart disease risk in 10494 cases and 15624 controls of European ancestry. Circulation 121:2284–2293PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Guo-Hua Zheng
    • 1
  • Shang-Quan Xiong
    • 2
  • Hai-Ying Chen
    • 1
  • Li-Juan Mei
    • 1
  • Ting Wang
    • 2
  1. 1.College of Rehabilitation MedicineFujian University of Traditional Chinese MedicineFuzhouChina
  2. 2.Department of Cardiologic MedicineThe People’s Hospital of Fujian ProvinceFuzhouChina

Personalised recommendations